Acumen Pharmaceuticals Files 2023 Annual Report on Form 10-K

Ticker: ABOS · Form: 10-K · Filed: Mar 26, 2024 · CIK: 1576885

Acumen Pharmaceuticals, INC. 10-K Filing Summary
FieldDetail
CompanyAcumen Pharmaceuticals, INC. (ABOS)
Form Type10-K
Filed DateMar 26, 2024
Risk Levelmedium
Pages15
Reading Time18 min
Key Dollar Amounts$0.0001, $1
Sentimentneutral

Sentiment: neutral

Topics: 10-K, Acumen Pharmaceuticals, Biotechnology, Financial Report, SEC Filing

TL;DR

<b>Acumen Pharmaceuticals, Inc. has filed its 2023 10-K report detailing financial performance and corporate activities.</b>

AI Summary

Acumen Pharmaceuticals, Inc. (ABOS) filed a Annual Report (10-K) with the SEC on March 26, 2024. Acumen Pharmaceuticals, Inc. filed its 2023 Form 10-K on March 26, 2024, reporting for the fiscal year ending December 31, 2023. The company is engaged in the Biological Products (No Diagnostic Substances) industry, SIC code 2836. Acumen Pharmaceuticals conducted a public offering on July 21, 2023. The filing details various financial instruments including common stock, additional paid-in capital, retained earnings, and accumulated other comprehensive income for the years 2021-2023. Information on employee stock options, convertible debt securities, and warrants is also provided for the fiscal years 2022 and 2023.

Why It Matters

For investors and stakeholders tracking Acumen Pharmaceuticals, Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Acumen Pharmaceuticals' financial health, operational activities, and strategic initiatives for the fiscal year 2023, which is crucial for investors to assess the company's current standing and future prospects. The detailed financial statements and disclosures within the 10-K are essential for understanding the company's capital structure, including equity, debt, and stock-based compensation, as well as its market positioning within the biotechnology sector.

Risk Assessment

Risk Level: medium — Acumen Pharmaceuticals, Inc. shows moderate risk based on this filing. The company is in the biotechnology sector, which is inherently high-risk due to long development cycles, regulatory hurdles, and significant R&D investment, as indicated by its focus on biological products.

Analyst Insight

Investors should review the detailed financial statements and risk factors in the 10-K to understand the company's financial position and the specific risks associated with its drug development pipeline.

Key Numbers

Key Players & Entities

FAQ

When did Acumen Pharmaceuticals, Inc. file this 10-K?

Acumen Pharmaceuticals, Inc. filed this Annual Report (10-K) with the SEC on March 26, 2024.

What is a 10-K filing?

A 10-K is a comprehensive annual financial report required by the SEC, covering audited financials, business operations, risk factors, and management discussion. This particular 10-K was filed by Acumen Pharmaceuticals, Inc. (ABOS).

Where can I read the original 10-K filing from Acumen Pharmaceuticals, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Acumen Pharmaceuticals, Inc..

What are the key takeaways from Acumen Pharmaceuticals, Inc.'s 10-K?

Acumen Pharmaceuticals, Inc. filed this 10-K on March 26, 2024. Key takeaways: Acumen Pharmaceuticals, Inc. filed its 2023 Form 10-K on March 26, 2024, reporting for the fiscal year ending December 31, 2023.. The company is engaged in the Biological Products (No Diagnostic Substances) industry, SIC code 2836.. Acumen Pharmaceuticals conducted a public offering on July 21, 2023..

Is Acumen Pharmaceuticals, Inc. a risky investment based on this filing?

Based on this 10-K, Acumen Pharmaceuticals, Inc. presents a moderate-risk profile. The company is in the biotechnology sector, which is inherently high-risk due to long development cycles, regulatory hurdles, and significant R&D investment, as indicated by its focus on biological products.

What should investors do after reading Acumen Pharmaceuticals, Inc.'s 10-K?

Investors should review the detailed financial statements and risk factors in the 10-K to understand the company's financial position and the specific risks associated with its drug development pipeline. The overall sentiment from this filing is neutral.

Risk Factors

Key Dates

Filing Stats: 4,498 words · 18 min read · ~15 pages · Grade level 16.3 · Accepted 2024-03-26 09:16:58

Key Financial Figures

Filing Documents

BUSINESS

BUSINESS 1 ITEM 1A.

RISK FACTORS

RISK FACTORS 28 ITEM 1B. UNRESOLVED STAFF COMMENTS 77 ITEM 1C. C YBERSECURITY 77 ITEM 2.

PROPERTIES

PROPERTIES 78 ITEM 3.

LEGAL PROCEEDINGS

LEGAL PROCEEDINGS 78 ITEM 4. MINE SAFETY DISCLOSURES 78 PART II 79 ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES 79 ITEM 6. [RESERVED] 79 ITEM 7.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 80 ITEM 7A.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 88 ITEM 8.

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA 89 ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE 113 ITEM 9A.

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES 113 ITEM 9B. OTHER INFORMATION 114 ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS 114 PART III 115 ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE 115 ITEM 11.

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 115 ITEM 12.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 115 ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE 115 ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES 115 PART IV 116 ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES. 116 ITEM 16. FORM 10-K SUMMARY 118

SIGNATURES

SIGNATURES 119 i Table of Contents SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Annual Report on Form 10-K including statements regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will" or "would" or the negative of these words or other similar terms or expressions. These forward-looking statements include, but are not limited to, statements concerning the following: the sufficiency of our existing cash and cash equivalents and marketable securities to fund our future operating expenses and capital expenditure requirements; our ability to obtain funding for our operations, including funding necessary to develop and commercialize sabirnetug, subject to obtaining necessary regulatory approvals; the ability of our clinical trials to demonstrate the safety and efficacy of sabirnetug, and other positive results; the therapeutic potential of sabirnetug, including its potential for improved safety and efficacy as compared to other monoclonal antibodies approved and or in development, as well as the expectations concerning the INTERCEPT-AD and ALTITUDE-AD clinical trials; the success, cost and timing of our development activities, nonclinical studies and clinical trials; the structure, timing and focus of our future clinical trials, and the reporting of data from those trials, including

Business

Item 1. Business. Overview We are a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what we believe to be a key underlying cause of Alzheimer's disease, or AD. Alzheimer's disease is a progressive neurodegenerative disease of the brain that leads to loss of memory and cognitive functions and ultimately results in death. Alzheimer's disease currently affects over 6 million people in the United States and approximately 32 million people worldwide and is the sixth-leading cause of death in the United States. However, due to the aging population, patient populations in the United States impacted by AD are expected to grow to approximately 13 million people by 2050 without effective preventative measures or safe and effective disease-modifying treatments. By 2050, healthcare costs for AD in the United States alone are estimated to exceed $1 trillion. Our scientific founders pioneered research on soluble amyloid-beta oligomers, or AOs, which are globular assemblies of the amyloid-beta, or A, peptide that are distinct from A monomers and amyloid plaques. Based on decades of research and supporting evidence, AOs have gained increasing scientific acceptance as a primary toxin involved in the initiation and propagation of AD pathology. We are currently focused on advancing a targeted immunotherapy drug candidate, sabirnetug* (ACU193), in clinical development following Phase 1 results in "early AD" patients (patients with mild cognitive impairment or mild dementia due to Alzheimer's pathology) that were reported in July 2023. Sabirnetug is a recombinant humanized immunoglobulin gamma 2, or IgG2, monoclonal antibody, or mAb, that was designed to selectively target AOs, has demonstrated functional and protective effects in in vitro assays, and has demonstrated in vivo safety and pharmacologic activity in multiple animal species, including transgenic mouse models for AD. Sabirnetug is the result of over a decade of research and

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing